The Vidcare evaluation was announced 15th August 2024, which...

The Vidcare evaluation was announced 15th August 2024, which stated a 4-6 month evaluation (we're at the 5 month mark).

The text you posted was from 3rd December 2024, and also stated: "Our opportunity to support Vidcare in their ambitious, Indian government supported initiative to bring in home testing to hypothyroidism, is another example of the potential near term opportunity for us in India. We have been discussing the framework for a commercial agreement to support their planned commercial launch from 2025, with potentially large opportunities ahead"

As for the Vidcare website, the Mu-Sure product has been available for purchase for at least 12 months

It was originally advertised as a subscription with no costing available
In April 2024 they started advertising it for R300
In August 2024 they increased the price to R499

"AnteoTech have been engaged with Vidcare from India since early 2024 to evaluate use of AnteoBind NXT in their TSH test known as the “Mu-sure”, for diagnosing hypothyroidism. AnteoTech have been able to demonstrate that AnteoBind NXT is highly effective at increasing activations of the particles
required in the Mu-sure test. Under the terms of this MOU, if the commercial evaluation achieves the designated technical hurdles, then the parties will negotiate a commercial agreement in good faith. If successful, Vidcare expect to launch their Mu-sure product in early 2025, where under-active thyroid is a major health challenge" 30 sep 2024

As for the product launching in 2025, despite having being available for purchase for the past 12+ months, that I cant answer.

(Bit off topic, but the '4C-Period ending 30 Sept 2024' has receipts of $349,000 whereby roughly $285,000 would have been from SII. I haven't been able to find an obvious source for the remaining 64,000 other than Vidcare)